Twist Bioscience (NASDAQ:TWST) Stock Price Down 4.4%

Twist Bioscience Co. (NASDAQ:TWST)’s share price traded down 4.4% on Tuesday . The stock traded as low as $27.90 and last traded at $27.95. 98,884 shares changed hands during trading, a decline of 89% from the average session volume of 907,806 shares. The stock had previously closed at $29.24.

Analyst Ratings Changes

TWST has been the topic of a number of research reports. The Goldman Sachs Group upgraded shares of Twist Bioscience from a “neutral” rating to a “buy” rating and upped their target price for the stock from $25.00 to $45.00 in a research report on Wednesday, January 17th. Barclays reduced their target price on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 10th. Finally, Scotiabank upped their target price on shares of Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a research report on Monday, February 5th.

Twist Bioscience Stock Down 2.5 %

The company’s fifty day moving average is $36.15 and its two-hundred day moving average is $29.89. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of -8.10 and a beta of 1.62.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Friday, February 2nd. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.03. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. The business had revenue of $71.50 million for the quarter, compared to analyst estimates of $67.59 million. During the same period in the prior year, the business posted ($0.74) earnings per share. Twist Bioscience’s revenue was up 31.8% compared to the same quarter last year. On average, equities research analysts expect that Twist Bioscience Co. will post -3.17 EPS for the current year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,487 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $37.43, for a total value of $55,658.41. Following the completion of the sale, the chief executive officer now owns 516,409 shares of the company’s stock, valued at $19,329,188.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Emily M. Leproust sold 1,487 shares of the stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $37.43, for a total transaction of $55,658.41. Following the completion of the sale, the chief executive officer now owns 516,409 shares of the company’s stock, valued at $19,329,188.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Emily M. Leproust sold 1,128 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $33.52, for a total transaction of $37,810.56. Following the sale, the chief executive officer now directly owns 515,281 shares of the company’s stock, valued at approximately $17,272,219.12. The disclosure for this sale can be found here. Insiders have sold 11,037 shares of company stock worth $384,092 over the last ninety days. Company insiders own 3.92% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Captrust Financial Advisors grew its position in Twist Bioscience by 101.3% in the second quarter. Captrust Financial Advisors now owns 759 shares of the company’s stock valued at $27,000 after purchasing an additional 382 shares in the last quarter. Federated Hermes Inc. bought a new position in Twist Bioscience in the third quarter valued at $29,000. China Universal Asset Management Co. Ltd. grew its position in Twist Bioscience by 96.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock valued at $30,000 after purchasing an additional 721 shares in the last quarter. EdgeRock Capital LLC bought a new position in Twist Bioscience in the fourth quarter valued at $30,000. Finally, KBC Group NV bought a new position in Twist Bioscience in the fourth quarter valued at $42,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.